ArticleCancer immunology, immunotherapy : CII2008
Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Tertiary lymphoid structures associated with improved survival and enhanced antitumor immunity in acral melanoma.NPJ precision oncology · 2025Article
- Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity.Neuro-oncology · 2025Article
- Turning up the heat: CTLA4 blockade in urothelial cancer.Nature reviews. Urology · 2024Review
- Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma.Frontiers in immunology · 2024Review
- Heterogeneity of tertiary lymphoid structures in cancer.Frontiers in immunology · 2023Review
- The link between T cell activation and development of functionally useful tumour-associated high endothelial venules.Discovery immunology · 2023Review
- Modulation of T cell function and survival by the tumor microenvironment.Frontiers in cell and developmental biology · 2023Review
- The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers.Journal of immunotherapy and precision oncology · 2022Review
- Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer.Medical oncology (Northwood, London, England) · 2022Review
- Role of tertiary lymphoid organs in the regulation of immune responses in the periphery.Cellular and molecular life sciences : CMLS · 2022Review
- Tumor necrosis factor receptor regulation of peripheral node addressin biosynthetic components in tumor endothelial cells.Frontiers in immunology · 2022Article
- Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses.Frontiers in cell and developmental biology · 2022Review
- Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy.Oncology letters · 2021Review
- High endothelial venules (HEVs) in immunity, inflammation and cancer.Angiogenesis · 2021Review
- The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity.Trends in cancer · 2021Review
- Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.Frontiers in immunology · 2021Review
- Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.Cellular & molecular immunology · 2019Review
- The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer.Frontiers in immunology · 2019Review
- Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
- Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously demonstrated that targeting lymphotoxin alpha (LTalpha) to the tumor evokes its immunological destruction in a syngeneic B16 melanoma model. Since treatment was associated with the induction of peritumoral tertiary lymphoid tissue, we speculated that the induced immune response was initiated at the tumor site. METHODS AND
resultsIn order to directly test this notion, we analyzed the efficacy of tumor targeted LTalpha in LTalpha knock-out (LTalpha(-/-)) mice which lack peripheral lymph nodes. To this end, we demonstrate that tumor-targeted LTalpha mediates the induction of specific T-cell responses even in the absence of secondary lymphoid organs. In addition, this effect is accompanied by the initiation of tertiary lymphoid tissue at the tumor site in which B and T lymphocytes are compartmentalized in defined areas and which harbor expanded numbers of tumor specific T cells as demonstrated by in situ TRP-2/K(b) tetramer staining. Mechanistically, targeted LTalpha therapy seems to induce changes at the tumor site which allows a coordinated interaction of immune competent cells triggering the induction of tertiary lymphoid tissue.
conclusionThus, our data demonstrate that targeted LTalpha promotes an accelerated immune response by enabling the priming of T cells at the tumor site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.